Current trends in antiglaucoma therapy

Bibliography

• QUIGLY HA: Open-angle glaucoma. New Engl. J. Med. (1993) 328:1097–1106.
   PubMed Web of Science ®Google Scholar
• ••This review provides an excellent introduction to open angle glaucoma and covers thedefinitions, epidemiology, pathophysiology and diagnosis of glaucoma.
   Google Scholar
• Ritch R, Shields MB, Krupin T (Eds.), Mosby-Yearbook, Inc., St. Louis, USA (1996):753–768.
   Google Scholar
• QUIGLEY HA: Number of people with glaucoma worldwide. Br. J. Ophthalmol. (1996) 80:389–393.
   PubMed Web of Science ®Google Scholar
• TIELSCH JM, SOMMER A, KATZ J, et al.: Racial variations in the prevalence of primary open-angle glaucoma: the Baltimore Eye Survey. JAMA (1991) 266:369–374.
   PubMed Web of Science ®Google Scholar
• KERRIGAN LA, ZACK DJ, QUIGLEY HA, et al.: TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch. Ophthalmol. (1997) 115:1031–1035.
   PubMed Web of Science ®Google Scholar
• FLAMMER J, ORGUL S: Optic nerve blood-flow abnormalities in glaucoma. Prog. Retin. Eye Res. (1998) 17:267–289.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO T, KITAZAWA Y: Vascular pathogenesis of normal-tension glaucoma: a possible pathogenetic factor, other than intraocular pressure, of glaucomatous optic neuropathy. Prog. Retin. Eye Res. (1998) 17:127–143.
   PubMed Web of Science ®Google Scholar
• DRYER EB, ZURAKOWSKI D, SCHUMER RA, et al.: Elevated glutamate levels in the vitreous body of human and monkeys with glaucoma. Arch. Ophthalmol. (1996) 114:299–305.
   PubMed Web of Science ®Google Scholar
• NEUFELD AH: New conceptual approaches for pharmacological neuroprotection in glaucomatous neuronal degeneration. J. Glaucoma (1998) 7:434–438.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ MR, PENA JDO: The optic nerve head in glaucomatous optic neuropathy. Arch. Ophthalmol. (1997) 115:389–395.
   PubMed Web of Science ®Google Scholar
• STONE EM, FINGERT JH, ALWARD WLM, et al.: Identification of a gene that causes primary open angle glaucoma. Science (1997) 275:668–670.
   PubMed Web of Science ®Google Scholar
• ALWARD WLM, FINGERT JH, COOTE MA, et al.: Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLC1A). New Engl. J. Med. (1998) 338:1022–1027.
   PubMed Web of Science ®Google Scholar
• BRUBAKER RF: Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am. J. Ophthalmol. (1996) 121:473–483.
   PubMed Web of Science ®Google Scholar
• PARSHLEY DE, BRADLEY JM, FISK A, et al.: Laser trabeculoplasty induces stromelysin expression by trabecular juxtacanalicular cells. Invest. Ophthalmol. Vis. Sci. (1996) 37:795–804.
   PubMed Web of Science ®Google Scholar
• VAN BUSKIRK EM: Editorial: the tale of normal-tension glaucoma. J. Glaucoma (1998)7:363–365.
   PubMed Web of Science ®Google Scholar
• SAGRUE MF: New approaches to antiglaucoma therapy. J. Med. Chem. (1997) 40:2793–2809.
   PubMed Web of Science ®Google Scholar
• ••This is an extensive review of the pharmacological classes of antiglaucoma agents andcontains over 240 references.
   Google Scholar
• ALWARD WLM: Medical management of glaucoma. New Engl. J. Med. (1998) 339:1298–1307.
   PubMed Web of Science ®Google Scholar
• ••This excellent, up-to-date review provides a glaucomatologist's perspective on currentglaucoma therapeutics.
   Google Scholar
• DAVID R: Changing therapeutic paradigms in glaucoma management. Exp. Opin. Invest. Drugs. (1998) 7:1063–1086.
   PubMedGoogle Scholar
• ••This review highlights some new and future glaucoma therapeutic agents and contains 300references.
   Google Scholar
• ALM A: Prostaglandin derivatives as ocular hypotensive agents. Prog. Retin. Eye Res. (1998)17:291–312.
   PubMed Web of Science ®Google Scholar
• WISTRAND PJ, STJERNSCHANTZ J, OLSSON K: The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv. Ophthalmol. (1997) 41\(Suppl. 2):S129–138.
   PubMedGoogle Scholar
• JOHNSTONE MA: Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am. J. Ophthalmol. (1997) 124:544–547.
   PubMed Web of Science ®Google Scholar
• WARWAR RE, BULLOCK JD, BALLAL D: Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology (1998) 105:263–268.
   PubMed Web of Science ®Google Scholar
• HELLBERG M, SALLEE V, MCLAUGHLIN MA, et al.: Preclinical efficacy of AL-6221, a potent and selective FP prostaglandin agonist [abstract]. Invest. Ophthalmol. Vis. Sci. (1998) 39:S420.
   Google Scholar
• WOODWARD DF, KRAUSS AH-P, CHEN J, et al.: Neutral replacement of the carboxylic group of prostaglandin F2a provides a novel series of ocular hypotensive lipids with pharmacological activity distinct from prostaglandins [abstract]. Invest. Ophthalmol. Vis. Sci. (1998) 39:S420.
   Google Scholar
• SILVER L, BRINZOLAMIDE PRIMARY THERAPY STUDY GROUP: Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am. J. Ophthalmol. (1998) 126:400–408.
   PubMed Web of Science ®Google Scholar
• BORIACK-SJODIN PA, ZEITLIN S, CHEN H-H et al.: Structural analysis of inhibitor binding to human carbonic anhydrase II. Protein Sci. (1998) 7:2483–2489.
   PubMed Web of Science ®Google Scholar
• PANG I-H, YORIO T: Ocular actions of endothelins. Proc. Soc. Exp. Biol. Med. (1997) 215:21–34.
   PubMed Web of Science ®Google Scholar
• ORGUL S, PUNTE C, FLAMMER J: Endothelium-derived vasoactive substances relevant to normal-tension glaucoma. Curr. Opin. Ophthalmol. (1998) 9:88–94.
   PubMed Web of Science ®Google Scholar
• TINGEY DP, SCHROEDER A, EPSTEIN MP, et al.: Effects of topical ethacrynic acid adducts on intraocular pressure in rabbits and monkeys. Arch. Ophthalmol. (1992) 110:699–702.
   PubMed Web of Science ®Google Scholar
• EPSTEIN DL, ROBERTS BC, SKINNER LL: Non-sulfhydryl-reactive phenoxyacetic acids increase aqueous humor outflow. Invest. Ophthalmol. Vis. Sci. (1997) 38:1526–1534.
   PubMedGoogle Scholar
• TIAN B, KAUFMAN PL, VOLBERG T, et al.: H-7 disrupts the actin cytoskeleton and increases outflow facility. Arch. Ophthalmol. (1998) 166:633–643.
   Google Scholar
• WISCONSIN ALUMNI RESEARCH FOUNDATION: U55798380 (1998).
   Google Scholar
• EPSTEIN DL, ROWLETTE L-L, ROBERTS BC: Acto-myosin drug effects and aqueous outflow function. Invest. Ophthalmol. Vis. Sci. (1999) 40:74–81.
   PubMed Web of Science ®Google Scholar
• Drance SM (Ed.), Kugler Publications, NY, USA (In Press).
   Google Scholar
• COLLIGNON-BRACH J: Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma. Surv. Ophthalmol. (1994) 38 (Suppl.) :S149–155.
   Google Scholar
• HOSTE AM, SYS SU: The relaxant action of betaxolol on isolated bovine retinal microarteries. Current Eye Res. (1994) 13:483–487.
   PubMed Web of Science ®Google Scholar
• HARRIS A, SPAETH GL, SERGOTT RC, et al.: Retrobulbar aterial hemodynamic effects of betaxolol and timolol in normal-tension glaucoma. Am. J. Ophthalmol. (1995) 120:168–175.
   PubMed Web of Science ®Google Scholar
• TURACLI ME, OZDEN RG, GURSES MA: The effect of betaxolol on ocular blood flow and visual fields in patients with normotension glaucoma. Eur. J. Ophthalmol. (1998) 8:62–66.
   PubMed Web of Science ®Google Scholar
• OSBORNE NN, CAZEVIELLE C, CARVALHO AL, et al.: In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res. (1997) 751:113–123.
   PubMed Web of Science ®Google Scholar
• YOLES E, WHEELER LA, SCHWARTZ M: a2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest. Ophthalmol. Vis. Sci. (1999) 40:65–73.
   PubMed Web of Science ®Google Scholar
• LEI RK, CHUN TY, HASSON DW, et al.: Brimonidine protects photoreceptors and visual function after light damage [abstract]. Invest. Ophthalmol. Vis. Sci. (1998) 39:S876.
   PubMed Web of Science ®Google Scholar
• HASSON D, LAI RK, CHUM T, et al.: Functional protection of rat retina from ischemic injury by brimonidine [abstract]. Soc. Neurosci. (1997) 23:168.
   Google Scholar
• MITCHELL CK, NGUYEN CK, FELDMAN RM: Neuroprotection of retinal ganglion cells [abstract]. Invest. Ophthalmol. Vis. Sci. (1998) 39:S261.
   Google Scholar
• WEN R, CHENG T, LI Y, et al.: Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo an dameliorate light damage. J. Neurosci. (1996) 16:5986–5992.
   PubMed Web of Science ®Google Scholar
• BARNES GE, LI B, DEAN T, et al.: Improvement of optic nerve blood flow after one-week b.i.d. topical CAI treatment with brinzolamide in the rabbit [abstract]. Invest. Ophthalmol. Vis. Sci. (1998) 39:S263.
   PubMed Web of Science ®Google Scholar
• GEORGOPOULOS G, DIESTELHORST M, FISCHER R, et al.: Short-term effect of latanoprost on ocular blood flow [abstract]. Invest. Ophthalmol. Vis. Sci. (1998) 39:S265.
   Google Scholar
• COLLABORATIVE NORMAL-TENSION GLAUCOMA STUDY GROUP: Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol. (1998) 126:487–497.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO T, NIWA Y, KAWAKAMI H, et al.: The effect of nilvadipine, a calcium channel-blocker, on the hemodynamics of retrobulbar vessels in normal-tension glaucoma. J. Glaucoma (1998) 7:301–305.
   PubMed Web of Science ®Google Scholar
• CHOI DW, ROTHMAN SM: The role of glutamate neurotoxicity in hypoxic-ischemic neuronal injury. Ann. Rev. Neurosci. (1990) 13:171–182.
   PubMed Web of Science ®Google Scholar
• LUCAS DR, NEWHOUSE JP: The toxic effect of sodium L-glutamate on the inner layers of the retina. Arch. Ophthalmol. (1957) 58:193–201.
   PubMed Web of Science ®Google Scholar
• DREYER EB: A proposed role for excitotoxicity in glaucoma. (1998) 7:62–67.
   Google Scholar
• SCHWARTZ M, BELKIN M, YOLES E, et al.: Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. J. Glaucoma (1996) 5:427–432.
   PubMed Web of Science ®Google Scholar
• VORWERK CK, LIPTON SA, ZURAKOWSKI D, et al.: Chronic low dose glutamate is toxic to retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. (1996) 37:1618–1624.
   PubMed Web of Science ®Google Scholar
• LAGREZE WA, KNORLE R, BACH M, et al.: Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. Invest. ophthalmol. Vis. Sci. (1998) 39:1063–1069.
   PubMed Web of Science ®Google Scholar
• REYES M, REYES A, OPITZ T, et al.: Eliprodil, a non-competitive, NR2B-selective NMDA antagonist, protects pyramidal neurons in hippocampal slices from hypoxic/ischemic damage. Brain Res. (1998) 782:212–218.
   PubMed Web of Science ®Google Scholar
• PANG I-H, WEXLER EM, NAVVY S, et al.: Protective effect of eliprodil against excitotoxicity in rat retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. (1999) (In Press).
   Google Scholar
• KAPIN MA, DOSHI R, SCATTON B, et al.: Neuroprotective effects of eliprodil in retinal excitotoxicity and ischemia. Invest. Ophthalmol. Vis. Sci. (1999) (In Press).
   Google Scholar
• YOLES E, BELKIN M, SCHWARTZ M: HU-211, a non-psychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy. J. Neurotrauma (1996) 13:49–57.
   PubMed Web of Science ®Google Scholar
• LUTJEN-DRECOLL E, MAY CA, POLANSKY JR, et al.: Localization of the stress proteinsaB-crystallin and trabecular meshwork inducible glucocorticoid response protein in normal and glaucomatous trabecular meshwork. Invest. Ophthalmol. Vis. Sci. (1998) 39:517–525.
   PubMed Web of Science ®Google Scholar
• POLANSKY JR, FAUSS DJ, CHEN P, et al.: Cellular pharmacology and molecular biology ofthe trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica (1997) 211:126–139.
   PubMed Web of Science ®Google Scholar